Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

OPZELURA 1.5% CREAM

ruxolitinib
$34.1433per GM

Strength

15 mg/g

Manufacturer

Incyte Corporation

NDC

50881000705

Classification

Brand

Dosage Form

CREAM

Route

TOPICAL

Last Updated

1/1/2026

Active Ingredients

RUXOLITINIB PHOSPHATE

Approval Type

New Drug (NDA)

FDA Application

NDA215309

On Market Since

9/21/2021

Pharmacological Classes

Janus Kinase Inhibitor
Janus Kinase Inhibitors
Kinase Inhibitor

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+2.0%

1Y

+1.6%

3Y

+6.2%

5Y

N/A

All

+9.3%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

ZORTRESS 0.5 MG TABLET
Brand
00078041420•Novartis Pharmaceuticals Corporation
$17.8041
per EA
ZORTRESS 0.75 MG TABLET
Brand
00078041520•Novartis Pharmaceuticals Corporation
$27.0419
per EA
XELJANZ 5 MG TABLET
Brand
00069100101•Pfizer Inc.
$73.8329
per EA
GLEEVEC 100 MG TABLET
Brand
00078040134•Novartis Pharmaceuticals Corporation
$90.8197
per EA
OLUMIANT 2 MG TABLET
Brand
00002418230•Eli Lilly and Company
$92.2936
per EA
TASIGNA 200 MG CAPSULE
Brand
00078052651•Novartis Pharmaceuticals Corporation
$94.1452
per EA
TASIGNA 200 MG CAPSULE
Brand
00078052687•Novartis Pharmaceuticals Corporation
$94.1452
per EA
XELJANZ 10 MG TABLET
Brand
00069100201•Pfizer Inc.
$103.5456
per EA
RHOPRESSA 0.02% OPHTH SOLUTION
Brand
70727049725•Alcon Laboratories, Inc.
$131.9200
per ML
ROCKLATAN 0.02%-0.005% EYE DRP
Brand
70727052925•Alcon Laboratories, Inc.
$139.6392
per ML

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy